天冬酰胺酶样蛋白1是原发性子宫内膜癌的独立预后标志物,且在转移灶中常缺失
在782例原发性子宫内膜癌、90例前驱病变和179个转移灶中评估ASRGL1表达,低表达预示疾病特异性生存差,多因素分析显示ASRGL1在全队列(HR 1.53)和子宫内膜样亚组(HR 2.64)中均为独立预后因素,转移灶中常缺失。
要点
- ASRGL1蛋白和mRNA低表达均预示疾病特异性生存差(P<0.001)。
- 多因素分析中ASRGL1为独立预后因素:全队列HR 1.53,子宫内膜样亚组HR 2.64。
- 低级别子宫内膜样原发肿瘤中ASRGL1低表达较少见,多数转移灶中ASRGL1缺失。
核心结论
- 在前瞻性背景下,ASRGL1被验证为子宫内膜癌的强预后生物标志物。
- ASRGL1缺失与侵袭性疾病和不良生存相关,并首次证明在整个子宫内膜癌患者群体中具有独立预后价值。
研究设计与样本
- 前瞻性收集的独立患者队列,评估782例原发性子宫内膜癌、90例前驱病变(复杂性非典型增生)和179个转移灶(来自87例患者)的ASRGL1免疫组化表达。
- 在237例原发肿瘤中检测ASRGL1 mRNA水平,并与生存和ASRGL1蛋白表达关联。
主要发现
- ASRGL1蛋白和mRNA低表达预示疾病特异性生存差(P<0.001)。
- 多因素生存分析中,ASRGL1在全患者队列中具有独立预后价值(HR 1.53,95%CI 1.04-2.26,P=0.031)。
- 在子宫内膜样亚组中,ASRGL1具有独立预后价值(HR 2.64,95%CI 1.47-4.74,P=0.001)。
- 低级别子宫内膜样原发肿瘤患者中ASRGL1低表达频率低于高级别子宫内膜样和非子宫内膜样原发肿瘤患者。
- 多数转移灶中ASRGL1缺失。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Loss of Asparaginase-like protein 1 (ASRGL1) has been suggested as a prognostic biomarker in endometrial carcinoma. Our objective was to validate this in a prospectively collected, independent patient cohort, and evaluate ASRGL1 expression in endometrial carcinoma precursor lesion and metastases. METHODS: 782 primary endometrial carcinomas, 90 precursor lesions (complex atypical hyperplasia), and 179 metastases (from 87 patients) were evaluated for ASRGL1 expression by immunohistochemistry in relation to clinical and histopathological data. ASRGL1 mRNA level was investigated in 237 primary tumors and related to survival and ASRGL1 protein expression. RESULTS: Low expression of ASRGL1 protein and ASRGL1 mRNA predicted poor disease specific survival (P<0.001). In multivariate survival analyses ASRGL1 had independent prognostic value both in the whole patient cohort (Hazard ratio (HR): 1.53, 95% confidence interval (CI): 1.04-2.26, P=0.031) and within the endometrioid subgroup (HR: 2.64, CI: 1.47-4.74, P=0.001). Low ASRGL1 expression was less frequent in patients with low grade endometrioid primary tumors compared to high grade endometrioid and non-endometrioid primary tumors, and ASRGL1 was lost in the majority of metastatic lesions. CONCLUSIONS: In a prospective setting ASRGL1 validates as a strong prognostic biomarker in endometrial carcinoma. Loss of ASRGL1 is associated with aggressive disease and poor survival, and is demonstrated for the first time to have independent prognostic value in the entire endometrial carcinoma patient population.
引用
- Fonnes T, Berg HF, Bredholt T, et al. Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions. Gynecol Oncol. 2017. PMID: 29096882. doi:10.1016/j.ygyno.2017.10.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。